<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240612001125&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240612001125&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 12 Jun 2024 04:11:28 +0000</lastbuilddate>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Pulmonary artery pseudoaneurysm due to COVID-19-associated pulmonary mucormycosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860736/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae355. doi: 10.1093/eurheartj/ehae355. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860736/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38860736</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae355>10.1093/eurheartj/ehae355</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860736</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Zihao Li</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Zhenhe Liu</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary artery pseudoaneurysm due to COVID-19-associated pulmonary mucormycosis</dc:title>
<dc:identifier>pmid:38860736</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae355</dc:identifier>
</item>
<item>
<title>Brugada syndrome: can polygenic risk scores help the clinician?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860730/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae364. doi: 10.1093/eurheartj/ehae364. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860730/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38860730</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae364>10.1093/eurheartj/ehae364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860730</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Elijah R Behr</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Brugada syndrome: can polygenic risk scores help the clinician?</dc:title>
<dc:identifier>pmid:38860730</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae364</dc:identifier>
</item>
<item>
<title>Challenge-skill balance in cardiac surgery: an attempt to explain sex-related differences in coronary surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae350. doi: 10.1093/eurheartj/ehae350. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38860698</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae350>10.1093/eurheartj/ehae350</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860698</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Gloria Faerber</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Challenge-skill balance in cardiac surgery: an attempt to explain sex-related differences in coronary surgery</dc:title>
<dc:identifier>pmid:38860698</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae350</dc:identifier>
</item>
<item>
<title>Accelerated high sensitivity troponin diagnostics: ready for an even faster pace?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860689/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae344. doi: 10.1093/eurheartj/ehae344. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860689/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38860689</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae344>10.1093/eurheartj/ehae344</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860689</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Evangelos Giannitsis</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>Hugo A Katus</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Accelerated high sensitivity troponin diagnostics: ready for an even faster pace?</dc:title>
<dc:identifier>pmid:38860689</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae344</dc:identifier>
</item>
<item>
<title>CD163&lt;sup>;+&lt;/sup>; Macrophages Induce Endothelial-to-Mesenchymal Transition in Atheroma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CD163^(+) macrophages provoke EndMT, which may promote plaque progression through fibrous cap thinning.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 11. doi: 10.1161/CIRCRESAHA.123.324082. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cell phenotype switching is increasingly being recognized in atherosclerosis. However, our understanding of the exact stimuli for such cellular transformations and their significance for human atherosclerosis is still evolving. Intraplaque hemorrhage is thought to be a major contributor to plaque progression in part by stimulating the influx of CD163<sup>+</sup> macrophages. Here, we explored the hypothesis that CD163 macrophages cause plaque progression through the induction of proapoptotic endothelial-to-mesenchymal transition (EndMT) within the fibrous cap.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Human coronary artery sections from CVPath's autopsy registry were selected for pathological analysis. Athero-prone <i>ApoE</i><sup><i>-/-</i></sup> and <i>ApoE</i><sup><i>-/-</i></sup><i>/CD163</i><sup><i>-/-</i></sup> mice were used for in vivo studies. Human peripheral blood mononuclear cell-induced macrophages and human aortic endothelial cells were used for in vitro experiments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 107 lesions with acute coronary plaque rupture, 55% had pathological evidence of intraplaque hemorrhage in nonculprit vessels/lesions. Thinner fibrous cap, greater CD163<sup>+</sup> macrophage accumulation, and a larger number of CD31/FSP-1 (fibroblast specific protein-1) double-positive cells and TUNEL positive cells in the fibrous cap were observed in nonculprit intraplaque hemorrhage lesions, as well as in culprit rupture sections versus nonculprit fibroatheroma sections. Human aortic endothelial cells cultured with supernatants from hemoglobin/haptoglobin-exposed macrophages showed that increased mesenchymal marker proteins (transgelin and FSP-1) while endothelial markers (VE-cadherin and CD31) were reduced, suggesting EndMT induction. Activation of NF-κB (nuclear factor kappa β) signaling by proinflammatory cytokines released from CD163<sup>+</sup> macrophages directly regulated the expression of Snail, a critical transcription factor during EndMT induction. Western blot analysis for cleaved caspase 3 and microarray analysis of human aortic endothelial cells indicated that apoptosis was stimulated during CD163<sup>+</sup> macrophage-induced EndMT. Additionally, <i>CD163</i> deletion in athero-prone mice suggested that CD163 is required for EndMT and plaque progression. Using single-cell RNA sequencing from human carotid endarterectomy lesions, a population of EndMT was detected, which demonstrated significant upregulation of apoptosis-related genes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CD163<sup>+</sup> macrophages provoke EndMT, which may promote plaque progression through fibrous cap thinning.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38860377</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324082>10.1161/CIRCRESAHA.123.324082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860377</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Masayuki Mori</dc:creator>
<dc:creator>Atsushi Sakamoto</dc:creator>
<dc:creator>Rika Kawakami</dc:creator>
<dc:creator>Liang Guo</dc:creator>
<dc:creator>Lotte Slenders</dc:creator>
<dc:creator>Jose Verdezoto Mosquera</dc:creator>
<dc:creator>Saikat Kumar B Ghosh</dc:creator>
<dc:creator>Marian Wesseling</dc:creator>
<dc:creator>Tatsuya Shiraki</dc:creator>
<dc:creator>Arielle Bellissard</dc:creator>
<dc:creator>Palak Shah</dc:creator>
<dc:creator>Craig C Weinkauf</dc:creator>
<dc:creator>Takao Konishi</dc:creator>
<dc:creator>Yu Sato</dc:creator>
<dc:creator>Anne Cornelissen</dc:creator>
<dc:creator>Kenji Kawai</dc:creator>
<dc:creator>Hiroyuki Jinnouchi</dc:creator>
<dc:creator>Weili Xu</dc:creator>
<dc:creator>Aimee E Vozenilek</dc:creator>
<dc:creator>Desiree Williams</dc:creator>
<dc:creator>Takamasa Tanaka</dc:creator>
<dc:creator>Teruo Sekimoto</dc:creator>
<dc:creator>Michael C Kelly</dc:creator>
<dc:creator>Raquel Fernandez</dc:creator>
<dc:creator>Alyssa Grogan</dc:creator>
<dc:creator>A J Coslet</dc:creator>
<dc:creator>Alisa Fedotova</dc:creator>
<dc:creator>Anjali Kurse</dc:creator>
<dc:creator>Michal Mokry</dc:creator>
<dc:creator>Maria E Romero</dc:creator>
<dc:creator>Frank D Kolodgie</dc:creator>
<dc:creator>Gerard Pasterkamp</dc:creator>
<dc:creator>Clint L Miller</dc:creator>
<dc:creator>Renu Virmani</dc:creator>
<dc:creator>Aloke V Finn</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>CD163&lt;sup>;+&lt;/sup>; Macrophages Induce Endothelial-to-Mesenchymal Transition in Atheroma</dc:title>
<dc:identifier>pmid:38860377</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324082</dc:identifier>
</item>
<item>
<title>Predicting Out-of-Hospital Cardiac Arrest in the General Population Using Electronic Health Records</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a population-based case-control study, machine learning models incorporating readily available EHR data showed reasonable discrimination and risk enrichment for OHCA in the general population. Salient factors associated with OCHA risk were myriad across the cardiovascular and noncardiovascular spectrum. Public health and tailored strategies for OHCA prediction and prevention will require incorporation of this complexity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11. doi: 10.1161/CIRCULATIONAHA.124.069105. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The majority of out-of-hospital cardiac arrests (OHCAs) occur among individuals in the general population, for whom there is no established strategy to identify risk. In this study, we assess the use of electronic health record (EHR) data to identify OHCA in the general population and define salient factors contributing to OHCA risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The analytical cohort included 2366 individuals with OHCA and 23 660 age- and sex-matched controls receiving health care at the University of Washington. Comorbidities, electrocardiographic measures, vital signs, and medication prescription were abstracted from the EHR. The primary outcome was OHCA. Secondary outcomes included shockable and nonshockable OHCA. Model performance including area under the receiver operating characteristic curve and positive predictive value were assessed and adjusted for observed rate of OHCA across the health system.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were significant differences in demographic characteristics, vital signs, electrocardiographic measures, comorbidities, and medication distribution between individuals with OHCA and controls. In external validation, discrimination in machine learning models (area under the receiver operating characteristic curve 0.80-0.85) was superior to a baseline model with conventional cardiovascular risk factors (area under the receiver operating characteristic curve 0.66). At a specificity threshold of 99%, correcting for baseline OHCA incidence across the health system, positive predictive value was 2.5% to 3.1% in machine learning models compared with 0.8% for the baseline model. Longer corrected QT interval, substance abuse disorder, fluid and electrolyte disorder, alcohol abuse, and higher heart rate were identified as salient predictors of OHCA risk across all machine learning models. Established cardiovascular risk factors retained predictive importance for shockable OHCA, but demographic characteristics (minority race, single marital status) and noncardiovascular comorbidities (substance abuse disorder) also contributed to risk prediction. For nonshockable OHCA, a range of salient predictors, including comorbidities, habits, vital signs, demographic characteristics, and electrocardiographic measures, were identified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a population-based case-control study, machine learning models incorporating readily available EHR data showed reasonable discrimination and risk enrichment for OHCA in the general population. Salient factors associated with OCHA risk were myriad across the cardiovascular and noncardiovascular spectrum. Public health and tailored strategies for OHCA prediction and prevention will require incorporation of this complexity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38860364</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069105>10.1161/CIRCULATIONAHA.124.069105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860364</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jessica Perry</dc:creator>
<dc:creator>Jennifer A Brody</dc:creator>
<dc:creator>Christine Fong</dc:creator>
<dc:creator>Jacob E Sunshine</dc:creator>
<dc:creator>Vikas N O'Reilly-Shah</dc:creator>
<dc:creator>Michael R Sayre</dc:creator>
<dc:creator>Thomas D Rea</dc:creator>
<dc:creator>Noah Simon</dc:creator>
<dc:creator>Ali Shojaie</dc:creator>
<dc:creator>Nona Sotoodehnia</dc:creator>
<dc:creator>Neal A Chatterjee</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Predicting Out-of-Hospital Cardiac Arrest in the General Population Using Electronic Health Records</dc:title>
<dc:identifier>pmid:38860364</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069105</dc:identifier>
</item>
<item>
<title>TRIM35 Monoubiquitinates H2B in Cardiac Cells, Implications for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings suggest that TRIM35 and the ^(K120)Ub-histone 2B epigenetic modification are molecular features of cardiomyocytes that can collectively predict dilated cardiomyopathy pathogenesis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 11. doi: 10.1161/CIRCRESAHA.123.324202. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The tumor suppressor and proapoptotic transcription factor P53 is induced (and activated) in several forms of heart failure, including cardiotoxicity and dilated cardiomyopathy; however, the precise mechanism that coordinates its induction with accessibility to its transcriptional promoter sites remains unresolved, especially in the setting of mature terminally differentiated (nonreplicative) cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Male and female control or TRIM35 (tripartite motif containing 35) overexpression adolescent (aged 1-3 years months) and adult (aged 4-6 years months) transgenic mice were used for all in vivo experiments. Primary adolescent or adult mouse cardiomyocytes were isolated from control or TRIM35 overexpression transgenic mice for all in vitro experiments. Adenovirus or small-interfering RNA was used for all molecular experiments to overexpress or knockdown, respectively, target genes in primary mouse cardiomyocytes. Patient dilated cardiomyopathy or nonfailing left ventricle samples were used for translational and mechanistic insight in human samples. Chromatin immunoprecipitation was used to assess P53 binding to its transcriptional promoter targets, and RNA sequencing was used to identify disease-specific signaling pathways.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Here, we show that E3-ubiquitin ligase TRIM35 can directly monoubiquitinate lysine-120 (K120) on histone 2B in postnatal mature cardiomyocytes. This epigenetic modification was sufficient to promote chromatin remodeling, accessibility of P53 to its transcriptional targets, and elongation of its transcribed mRNA. We found that increased P53 transcriptional activity (in cardiomyocyte-specific <i>Trim35</i> overexpression transgenic mice) was sufficient to initiate heart failure and these molecular findings were recapitulated in nonischemic human LV dilated cardiomyopathy samples.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings suggest that TRIM35 and the <sup>K120</sup>Ub-histone 2B epigenetic modification are molecular features of cardiomyocytes that can collectively predict dilated cardiomyopathy pathogenesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38860363</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324202>10.1161/CIRCRESAHA.123.324202</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860363</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Maria Areli Lorenzana-Carrillo</dc:creator>
<dc:creator>Saymon Tejay</dc:creator>
<dc:creator>Joseph Nanoa</dc:creator>
<dc:creator>Guocheng Huang</dc:creator>
<dc:creator>Yongsheng Liu</dc:creator>
<dc:creator>Alois Haromy</dc:creator>
<dc:creator>Yuan Yuan Zhao</dc:creator>
<dc:creator>Michelle Mendiola Pla</dc:creator>
<dc:creator>Dawn E Bowles</dc:creator>
<dc:creator>Adam Kinnaird</dc:creator>
<dc:creator>Evangelos D Michelakis</dc:creator>
<dc:creator>Gopinath Sutendra</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>TRIM35 Monoubiquitinates H2B in Cardiac Cells, Implications for Heart Failure</dc:title>
<dc:identifier>pmid:38860363</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324202</dc:identifier>
</item>
<item>
<title>Correction to: Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease: Using a Genetic Risk Score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):e1414. doi: 10.1161/CIR.0000000000001262. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857334</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001262>10.1161/CIR.0000000000001262</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857334</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease: Using a Genetic Risk Score</dc:title>
<dc:identifier>pmid:38857334</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001262</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857333/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):e1413. doi: 10.1161/CIR.0000000000001263. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857333/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857333</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001263>10.1161/CIR.0000000000001263</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857333</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38857333</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001263</dc:identifier>
</item>
<item>
<title>Correction to: 2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857332/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):e1411. doi: 10.1161/CIR.0000000000001260. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857332/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857332</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001260>10.1161/CIR.0000000000001260</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857332</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</dc:title>
<dc:identifier>pmid:38857332</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001260</dc:identifier>
</item>
<item>
<title>Correction to: Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857331/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):e1412. doi: 10.1161/CIR.0000000000001261. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857331/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857331</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001261>10.1161/CIR.0000000000001261</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857331</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38857331</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001261</dc:identifier>
</item>
<item>
<title>A Concept of "Athero-Oncology": Tumor-Like Smooth Muscle Cells Drive Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857330/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):1899-1902. doi: 10.1161/CIRCULATIONAHA.124.069446. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857330/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857330</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069446>10.1161/CIRCULATIONAHA.124.069446</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857330</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Payel Chatterjee</dc:creator>
<dc:creator>Kathleen A Martin</dc:creator>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Concept of "Athero-Oncology": Tumor-Like Smooth Muscle Cells Drive Atherosclerosis</dc:title>
<dc:identifier>pmid:38857330</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069446</dc:identifier>
</item>
<item>
<title>Novel Mouse Model for Selective Tagging, Purification, and Manipulation of Cardiac Myofibroblasts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857329/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):1931-1934. doi: 10.1161/CIRCULATIONAHA.123.067754. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857329/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857329</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067754>10.1161/CIRCULATIONAHA.123.067754</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857329</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vaibhao Janbandhu</dc:creator>
<dc:creator>Vikram Tallapragada</dc:creator>
<dc:creator>Jinyuan Vero Li</dc:creator>
<dc:creator>Bharti Shewale</dc:creator>
<dc:creator>Shila Ghazanfar</dc:creator>
<dc:creator>Ralph Patrick</dc:creator>
<dc:creator>Charles D Cox</dc:creator>
<dc:creator>Richard P Harvey</dc:creator>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Mouse Model for Selective Tagging, Purification, and Manipulation of Cardiac Myofibroblasts</dc:title>
<dc:identifier>pmid:38857329</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067754</dc:identifier>
</item>
<item>
<title>PVC or Not PVC? That Is the Question</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857328/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):1927-1930. doi: 10.1161/CIRCULATIONAHA.124.069404. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857328/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857328</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069404>10.1161/CIRCULATIONAHA.124.069404</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857328</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Pierre Groussin</dc:creator>
<dc:creator>Alex Melot</dc:creator>
<dc:creator>Raphaël P Martins</dc:creator>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>PVC or Not PVC? That Is the Question</dc:title>
<dc:identifier>pmid:38857328</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069404</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):1921-1926. doi: 10.1161/CIRCULATIONAHA.124.070462. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857327</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070462>10.1161/CIRCULATIONAHA.124.070462</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857327</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38857327</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070462</dc:identifier>
</item>
<item>
<title>Fifty Years of Cardiovascular Magnetic Resonance: Continuing Evolution Toward the "One-Stop Shop" for Cardiovascular Diagnosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857326/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):1859-1861. doi: 10.1161/CIRCULATIONAHA.124.068244. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857326</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068244>10.1161/CIRCULATIONAHA.124.068244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857326</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>W Gregory Hundley</dc:creator>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fifty Years of Cardiovascular Magnetic Resonance: Continuing Evolution Toward the "One-Stop Shop" for Cardiovascular Diagnosis</dc:title>
<dc:identifier>pmid:38857326</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068244</dc:identifier>
</item>
<item>
<title>Letter by Andreotti et al Regarding Article, "Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857325/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):e1312. doi: 10.1161/CIRCULATIONAHA.124.069221. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857325/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857325</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069221>10.1161/CIRCULATIONAHA.124.069221</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857325</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:creator>Francesco Burzotta</dc:creator>
<dc:creator>Aldo Pietro Maggioni</dc:creator>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Andreotti et al Regarding Article, "Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance"</dc:title>
<dc:identifier>pmid:38857325</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069221</dc:identifier>
</item>
<item>
<title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38857319/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):1-3. doi: 10.1161/CIR.0000000000001208. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38857319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38857319</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001208>10.1161/CIR.0000000000001208</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38857319</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</dc:title>
<dc:identifier>pmid:38857319</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001208</dc:identifier>
</item>
<item>
<title>Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38856678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this large cohort of patients with HoFH, evinacumab was generally well tolerated and markedly decreased LDL-C irrespective of age and sex. Moreover, the efficacy and safety of evinacumab was sustained over the long term.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 10:ehae325. doi: 10.1093/eurheartj/ehae325. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by severely elevated LDL cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. In the pivotal Phase 3 HoFH trial (NCT03399786), evinacumab significantly decreased LDL-C in patients with HoFH. This study assesses the long-term safety and efficacy of evinacumab in adult and adolescent patients with HoFH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this open-label, single-arm, Phase 3 trial (NCT03409744), patients aged ≥12 years with HoFH who were evinacumab-naïve or had previously received evinacumab in other trials (evinacumab-continue) received intravenous evinacumab 15 mg/kg every 4 weeks with stable lipid-lowering therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 116 patients (adults: n = 102; adolescents: n = 14) were enrolled, of whom 57 (49.1%) were female. Patients were treated for a median (range) duration of 104.3 (28.3-196.3) weeks. Overall, treatment-emergent adverse events (TEAEs) and serious TEAEs were reported in 93 (80.2%) and 27 (23.3%) patients, respectively. Two (1.7%) deaths were reported (neither was considered related to evinacumab). Three (2.6%) patients discontinued due to TEAEs (none were considered related to evinacumab). From baseline to Week 24, evinacumab decreased mean LDL-C by 43.6% [mean (standard deviation, SD), 3.4 (3.2) mmol/L] in the overall population; mean LDL-C reduction in adults and adolescents was 41.7% [mean (SD), 3.2 (3.3) mmol/L] and 55.4% [mean (SD), 4.7 (2.5) mmol/L], respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this large cohort of patients with HoFH, evinacumab was generally well tolerated and markedly decreased LDL-C irrespective of age and sex. Moreover, the efficacy and safety of evinacumab was sustained over the long term.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38856678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38856678</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae325>10.1093/eurheartj/ehae325</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38856678</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Susanne Greber-Platzer</dc:creator>
<dc:creator>Laurens F Reeskamp</dc:creator>
<dc:creator>Gabriella Iannuzzo</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Samir Saheb</dc:creator>
<dc:creator>Claudia Stefanutti</dc:creator>
<dc:creator>Erik Stroes</dc:creator>
<dc:creator>Albert Wiegman</dc:creator>
<dc:creator>Traci Turner</dc:creator>
<dc:creator>Shazia Ali</dc:creator>
<dc:creator>Poulabi Banerjee</dc:creator>
<dc:creator>Tiera Drewery</dc:creator>
<dc:creator>Jennifer McGinniss</dc:creator>
<dc:creator>Alpana Waldron</dc:creator>
<dc:creator>Richard T George</dc:creator>
<dc:creator>Xue-Qiao Zhao</dc:creator>
<dc:creator>Robert Pordy</dc:creator>
<dc:creator>Jian Zhao</dc:creator>
<dc:creator>Eric Bruckert</dc:creator>
<dc:creator>Frederick J Raal</dc:creator>
<dc:date>2024-06-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy</dc:title>
<dc:identifier>pmid:38856678</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae325</dc:identifier>
</item>
<item>
<title>ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38856677/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 10:ehae321. doi: 10.1093/eurheartj/ehae321. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38856677/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38856677</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae321>10.1093/eurheartj/ehae321</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38856677</guid>
<pubDate>Mon, 10 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Seyed Saeed Tamehri Zadeh</dc:creator>
<dc:creator>Dick C Chan</dc:creator>
<dc:date>2024-06-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab</dc:title>
<dc:identifier>pmid:38856677</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae321</dc:identifier>
</item>
<item>
<title>MTFP1 controls mitochondrial fusion to regulate inner membrane quality control and maintain mtDNA levels</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38851188/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612001125&amp;v=2.18.0.post9+e462414
      <description>Mitochondrial dynamics play a critical role in cell fate decisions and in controlling mtDNA levels and distribution. However, the molecular mechanisms linking mitochondrial membrane remodeling and quality control to mtDNA copy number (CN) regulation remain elusive. Here, we demonstrate that the inner mitochondrial membrane (IMM) protein mitochondrial fission process 1 (MTFP1) negatively regulates IMM fusion. Moreover, manipulation of mitochondrial fusion through the regulation of MTFP1 levels...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 5:S0092-8674(24)00526-9. doi: 10.1016/j.cell.2024.05.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mitochondrial dynamics play a critical role in cell fate decisions and in controlling mtDNA levels and distribution. However, the molecular mechanisms linking mitochondrial membrane remodeling and quality control to mtDNA copy number (CN) regulation remain elusive. Here, we demonstrate that the inner mitochondrial membrane (IMM) protein mitochondrial fission process 1 (MTFP1) negatively regulates IMM fusion. Moreover, manipulation of mitochondrial fusion through the regulation of MTFP1 levels results in mtDNA CN modulation. Mechanistically, we found that MTFP1 inhibits mitochondrial fusion to isolate and exclude damaged IMM subdomains from the rest of the network. Subsequently, peripheral fission ensures their segregation into small MTFP1-enriched mitochondria (SMEM) that are targeted for degradation in an autophagic-dependent manner. Remarkably, MTFP1-dependent IMM quality control is essential for basal nucleoid recycling and therefore to maintain adequate mtDNA levels within the cell.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38851188/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612001125&v=2.18.0.post9+e462414">38851188</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.017>10.1016/j.cell.2024.05.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38851188</guid>
<pubDate>Sat, 08 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Luis Carlos Tábara</dc:creator>
<dc:creator>Stephen P Burr</dc:creator>
<dc:creator>Michele Frison</dc:creator>
<dc:creator>Suvagata R Chowdhury</dc:creator>
<dc:creator>Vincent Paupe</dc:creator>
<dc:creator>Yu Nie</dc:creator>
<dc:creator>Mark Johnson</dc:creator>
<dc:creator>Jara Villar-Azpillaga</dc:creator>
<dc:creator>Filipa Viegas</dc:creator>
<dc:creator>Mayuko Segawa</dc:creator>
<dc:creator>Hanish Anand</dc:creator>
<dc:creator>Kasparas Petkevicius</dc:creator>
<dc:creator>Patrick F Chinnery</dc:creator>
<dc:creator>Julien Prudent</dc:creator>
<dc:date>2024-06-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>MTFP1 controls mitochondrial fusion to regulate inner membrane quality control and maintain mtDNA levels</dc:title>
<dc:identifier>pmid:38851188</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.017</dc:identifier>
</item>





























</channel>
</rss>